Dr. Reddy's Laboratories 경영진

경영진 기준 점검 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Erez Israeli

최고경영자

₹230.3m

총 보수

CEO 급여 비율	n/a
CEO 재임 기간	8.2yrs
CEO 지분 보유율	n/a
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	4.4yrs

최근 경영진 업데이트

Recent updates

CEO 보수 분석

Erez Israeli의 보수는 Dr. Reddy's Laboratories의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	₹230m	n/a	₹43b
Dec 31 2025	n/a	n/a	₹57b
Sep 30 2025	n/a	n/a	₹59b
Jun 30 2025	n/a	n/a	₹57b
Mar 31 2025	₹175m	n/a	₹57b
Dec 31 2024	n/a	n/a	₹54b
Sep 30 2024	n/a	n/a	₹53b
Jun 30 2024	n/a	n/a	₹56b
Mar 31 2024	₹197m	n/a	₹56b
Dec 31 2023	n/a	n/a	₹52b
Sep 30 2023	n/a	n/a	₹51b
Jun 30 2023	n/a	n/a	₹47b
Mar 31 2023	₹195m	n/a	₹45b
Dec 31 2022	n/a	n/a	₹36b
Sep 30 2022	n/a	n/a	₹31b
Jun 30 2022	n/a	n/a	₹30b
Mar 31 2022	₹127m	n/a	₹24b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹19b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹120m	n/a	₹17b
Dec 31 2020	n/a	n/a	₹21b
Sep 30 2020	n/a	n/a	₹15b
Jun 30 2020	n/a	n/a	₹19b
Mar 31 2020	₹195m	₹107m	₹19b

보상 대 시장: Erez의 총 보수(USD2.41M)는 German 시장에서 비슷한 규모 기업의 평균(USD5.53M)보다 낮습니다.

보상과 수익: Erez의 보상은 20% 이상 증가했지만 지난 1년 동안 회사 수익은 20% 이상 감소했습니다.

CEO

Erez Israeli (58 yo)

8.2yrs

재임 기간

₹230,330,000

보수

Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...

리더십 팀

이름	직위	재임 기간	보수	지분
Gunupati Prasad	Co-Chairman	40.2yrs	₹158.17m	13.07% € 1.3b
Kallam Reddy	Chairman of the Board & Member of the Management Council	33.4yrs	₹100.66m	13.61% € 1.3b
Erez Israeli	CEO & Member of the Management Council	8.2yrs	₹230.33m	데이터 없음
Mannam Venkatanarasimham	CFO & Member of the Management Council	1.8yrs	₹72.48m	0.0074% € 707.6k
Krishna Venkatesh	Global Head of IPDO	2.4yrs	₹41.18m	데이터 없음
Deepak Sapra	Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council	no data	₹50.89m	0.0091% € 872.9k
Motupalli Ramana	CEO of Global Generics & Member of Management Council	no data	₹89.25m	0.0082% € 787.4k
Sanjay Sharma	Executive VP	8.8yrs	₹71.07m	데이터 없음
Patrick Aghanian	Head of Consumer Health Organization & Member of Management Council	no data	₹107.54m	데이터 없음
Bhethanabottla Phanimitra	Chief Digital & Information Officer and Member of the Management Council	2.8yrs	₹37.54m	0.0010% € 100.9k
Milan Kalawadia	CEO of North America & Member of Management Council	2.1yrs	₹86.78m	0.0057% € 546.1k
M S Sundar	Global Head of Quality and PV & Member of Management Council	less than a year	데이터 없음	0.0043% € 411.5k

2.4yrs

평균 재임 기간

57yo

평균 나이

경험이 풍부한 관리: RDDA의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.4 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Gunupati Prasad	Co-Chairman	40.2yrs	₹158.17m	13.07% € 1.3b
Kallam Reddy	Chairman of the Board & Member of the Management Council	33.4yrs	₹100.66m	13.61% € 1.3b
Claudio Albrecht	Independent Director	3.1yrs	₹20.24m	데이터 없음
Arun Kumar	Independent Director	3.8yrs	₹22.14m	데이터 없음
Shikha Sharma	Independent Director	7.4yrs	₹16.45m	데이터 없음
Leo Puri	Lead Independent Director	7.7yrs	₹22.62m	데이터 없음
Kodumudi Krishnan	Independent Director	4.4yrs	₹14.18m	데이터 없음
Sanjiv Mehta	Independent Director	2.5yrs	₹17.40m	데이터 없음
Alpna Seth	Independent Director	3.4yrs	₹19.77m	데이터 없음
Penny Wan	Independent Director	4.4yrs	₹20.72m	데이터 없음

4.4yrs

평균 재임 기간

66yo

평균 나이

경험이 풍부한 이사회: RDDA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.4 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/06/10 01:31
종가	2026/06/10 00:00
수익	2026/03/31
연간 수익	2026/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Dr. Reddy's Laboratories Limited는 69명의 분석가가 다루고 있습니다. 이 중 37명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Rohit Bhat	360 ONE Capital Market Private Limited
Gaurav Tinani	Ambit Capital
null null	Anand Rathi Shares and Stock Brokers Limited

Dr. Reddy's Laboratories 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 24, 2025

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Recent updates

Dr. Reddy’S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada

Dr. Reddy's Laboratories Limited announces Annual dividend, payable on August 22, 2026

Dr Reddys Laboratories Ltd Receives Health Canada Approval For Generic Semaglutide Injection

Enspirit Technology Services Private Limited entered into an agreement to acquire Svaas Wellness Limited from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 22.3 million.

CORONA Remedies Limited (NSEI:CORONA) acquired Wokadine Brand from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Limited to Report Q4, 2026 Results on May 12, 2026

Dr. Reddy's Announces USFDA Acceptance to Review its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Dr. Reddy's Laboratories Ltd. Announces the Launch of Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%

Dr. Reddy's Laboratories Limited to Report Q3, 2026 Results on Jan 21, 2026

USFDA Inspection Closes with Voluntary Action Indicated Classification

Eisai Co., Ltd. Announces Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for AVT03 (denosumab), A Proposed Biosimilar of Prolia®? and Xgeva®?

Dr. Reddy's Laboratories Limited to Report Q2, 2026 Results on Oct 24, 2025

Extrovis AG and Dr. Reddy's Announce the Launch of the Authorized Generic of Carac (Fluorouracil Cream), 0.5% in the U.S

Dr. Reddy's Laboratories Limited to Report Q1, 2026 Results on Jul 23, 2025

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 24, 2025

Dr. Reddy's Laboratories Limited Recommends A Final Dividend for the Financial Year 2024-25

Dr. Reddy's Laboratories Limited to Report Q4, 2025 Results on May 09, 2025

Dr. Reddy's Issues Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 Mg/100 mL, in the U.S., Due to Mislabeling of Infusion Bag

Senores Pharmaceuticals, Inc. agreed to acquire basket of 14 Abbreviated New Drug Applications from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Provides Lawsuit Updates

Dr. Reddy's Laboratories Limited to Report Q3, 2025 Results on Jan 23, 2025

Dr. Reddy's Laboratories Ltd. Launches Toripalimab in India

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Complaint Made Public in the United States District Court for the District of New Jersey

Dr. Reddy's Laboratories Limited to Report Q2, 2025 Results on Nov 05, 2024

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Fiscal Year 2024

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market